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Introduction
Antithrombotic therapies represent a key point in the
management of patients with acute coronary syndromes (ACS),
where the innovations in the pharmacological field and early
aggressive strategies have led to a significant improvement in
clinical outcomes [1–4].
Antiplatelet ADP-antagonists such as prasugrel, in particular,
have demonstrated a reduction in major adverse ischemic events
[5], overwhelming those complex metabolic interactions that
contribute to the interindividual variability or a more delayed
platelet inhibition with clopidogrel [6,7].
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A B S T R A C T
Background: ADP-antagonists such as prasugrel have reduced but yet not overcome the phenomenon of
high-on treatment platelet reactivity (HRPR), that has been shown to increase the rate of major
cardiovascular events after an acute coronary syndrome (ACS) or percutaneous coronary intervention
(PCI). However, the exact prevalence and the principal determinants of suboptimal platelet inhibition in
patients treated with dual antiplatelet therapy (DAPT) with prasugrel have not been completely clarified
and were therefore the aim of the present study.
Methods: We included patients (<75 years and >60 kg) treated with DAPT (aspirin + prasugrel) after PCI,
mainly for an ACS. Platelet function test evaluation was performed at 1–3 months from discharge. HRPR
was assessed by multiplate impedance aggregometry and defined for results above upper limit of normal
after ADP stimulation.
Results: We included 190 post-ACS patients. HRPR with prasugrel was observed in 19 patients (10%). The
prevalence of HRPR was stable in different high-risk subgroups of patients (female gender,
hypercholesterolemic, and chronic kidney disease) whereas it was increased in diabetic patients
(p = 0.045), with a significant interaction between diabetic status and HRPR (p = 0.04). However, at
multivariate analysis, an impaired metabolic status, with higher levels of glycosylated hemoglobin and
low-density lipoprotein (LDL) cholesterol, but not diabetic status, emerged as independent predictors of
HRPR with prasugrel [OR (95% CI) = 2.1 (1.32–3.33), p = 0.002 and OR (95% CI) = 1.03 (1.01–1.05),
p = 0.003, respectively], with a stronger linear relationship between ADP-mediated platelet aggregation
and glycosylated hemoglobin levels (r = 0.24, p = 0.002), than for LDL-cholesterol (r = 0.13, p = 0.09).
Conclusions: In post-ACS patients treated with PCI and receiving DAPT with prasugrel, HRPR is observed
in about 10% of patients. Impaired metabolic status, and especially elevated glycosylated hemoglobin,
emerged as independent predictors of the suboptimal effectiveness of prasugrel.
© 2018 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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However, recent studies have underlined the occurrence of a
suboptimal platelet inhibition, or residual high-on treatment
platelet reactivity (HRPR), even with newer antiplatelet drugs
[8,9]. Indeed, inadequate platelet inhibition has been associated
with a 2–9-fold increased risk of recurrent ischemic and
thrombotic events, although it is still debated whether tailoring
antiplatelet therapy could be more effective than a standard
therapy in achieving a therapeutic window with dual antiplatelet
therapy (DAPT) [10,11].
Variable rates (0–25%) of patients treated with prasugrel [12,13]
have been reported to display HRPR, thus preventing the expected
benefits of a more potent antiplatelet strategy, and especially in
acute phase settings and in higher risk subsets of patients such as
diabetics [14]. Nevertheless, in the absence of a standardized
definition for HRPR assessment, the exact prevalence and clinical
factors associated with an impaired response to prasugrel are still
largely undefined, and were therefore the aim of the present study.
Methods
We included patients admitted to the Division of Cardiology,
“Maggiore della Carità” Hospital, Eastern Piedmont University in
Novara, Italy, from September 2013 to March 2016 and undergoing
percutaneous coronary revascularization, mainly for an acute
coronary syndrome. All patients receiving at discharge DAPT with
aspirin (100–160 mg daily) and prasugrel (10 mg daily) were
scheduled for chemistry and platelet function test evaluation at 1–
3 months from discharge. The study was approved by our local
Ethical Committee and informed consent was obtained by all
patients.
Main demographic, clinical, and angiographic data, together
with the indication for DAPT were recorded at discharge and
included in a dedicated database, protected by password. Main
cardiovascular risk factors were identified: hypertension was
defined as systolic pressure >140 mmHg and/or diastolic pressure
>90 mmHg or if the individual was taking antihypertensive
medications. The diagnosis of diabetes was based on previous
history of diabetes treated with or without drug therapies, fasting
glucose >126 g/dl or HbA1c >6.5% at the moment of admission
[15]. Compliance was assessed on the day of the scheduled platelet
function test. Exclusion criteria were: patients’ refusal or if the
patient had given up prasugrel therapy, age 75 years, or body
weight 60 kg.
Biochemistry analysis
Blood samples were drawn in the early morning, following a
fasting period of 12 h. Glucose, creatinine, glycosylated hemoglo-
bin, and lipid profile were determined as previously described
[16]. Blood cell count was performed in a blood sample collected in
tripotassium ethylenediaminetetraacetic acid (7.2 mg) tubes.
These blood samples were analyzed within 2 h of venepuncture
by automatic blood cells counter (A Sysmex XE-2100, Sysmex
Europe GmbH).
Platelet aggregation
Platelet aggregation was determined by multiplate electrical
impedance aggregometry (MEA) in the early morning (>12 h after
last prasugrel dose). The aggregation tests were performed from
30 min to 2 h from blood collection [17]. Platelet aggregation was
assessed after stimulation with arachidonic acid (0.5 mM) (ASPI
test), collagen (3.2 mg/ml) (COL test), ADP (6.4 mM) with prosta-
glandin E1, and thrombin receptor activating peptide (TRAP-6;
30 mM). Results were expressed as arbitrary Aggregation Units
(AU) and plotted against time recorded for 6 min, defining platelet
function as the area under curve (AUC). HRPR for prasugrel was
defined for ADP test above 417 AUC (normal range: 417–1030)
[18,19]. The test was repeated in patients with HRPR to confirm the
finding.
Statistical analysis
All statistical analyses were performed by SPSS Statistics
Software 22.0 (IBM SPSS Inc., Chicago, IL, USA). Continuous
variables were represented as mean  SD, while categorical
variables as percentages. For non-normally distributed variables
median and interquartile range [IQR] were reported. Patients were
grouped according to the definition of HRPR. Chi-squared and
ANOVA test were appropriately used to compare clinical and
laboratory features between patients with and without HRPR. Non-
parametric test for the comparison of medians was applied for
non-normally distributed variables. Linear regression analysis was
performed between platelet aggregation AUC and continuous
variables associated with HRPR. Forward multiple logistic regres-
sion analysis was performed to evaluate independent predictors of
HRPR, among the variables significantly associated with HRPR at
univariate analysis (all variables with p < 0.05). Odds ratios for
continuous variables were considered per unitary linear increase.
A p-value <0.05 was considered statistically significant.
Results
Our population is represented by 190 patients undergoing
coronary stenting, mainly post-ACS. The main demographic,
clinical, and laboratory features of our population are listed in
Table 1. HRPR with prasugrel was observed in 19 patients (10%).
The test was repeated in all patients with HRPR, confirming the
finding in all of them.
As shown in Table 1, patients with HRPR were more frequently
diabetic (p = 0.015) and displayed higher levels of glycosylated
hemoglobin and low-density lipoprotein (LDL) cholesterol
(p = 0.003 and p = 0.001, respectively) and white blood cells
(p = 0.05). No differences were observed in other demographic,
clinical, or angiographic variables, but for a higher prevalence of
severe multivessel coronary disease in patients with HRPR
(p = 0.03). Mean platelet reactivity in HRPR patients was markedly
enhanced in response to all activating stimuli (p < 0.001 for ASPI
test, ADP test, COL test, and TRAP test).
As shown in Fig. 1, the prevalence of HRPR was stable in
different high-risk subgroups of patients, such as in female gender
(10.1% vs. 9.1%, p = 0.99) and patients with chronic kidney disease
(0% vs. 10.7%, p = 0.37), whereas it was relevantly increased in
diabetic patients (15.9% vs. 6.5%, p = 0.045), with a significant
interaction between diabetic status and HRPR (p = 0.04).
However, at multivariate analysis, an impaired metabolic
status, with higher levels of glycosylated hemoglobin and LDL
cholesterol, but not diabetic status, emerged as independent
predictors of HRPR with prasugrel [OR (95% CI) = 2.1 (1.32–3.33),
p = 0.002 and OR (95% CI) = 1.03 (1.01–1.05), p = 0.003, respective-
ly]. Complete data from the multivariable model are shown in
Table 2.
Moreover, as displayed in Fig. 2, a stronger linear relationship
was observed between ADP-mediated platelet aggregation and
glycosylated hemoglobin levels (r = 0.24, p = 0.002, Fig. 2A), than
for LDL cholesterol (r = 0.13, p = 0.09, Fig. 2B).
Discussion
The present study represents one of the largest cohorts of
patients chronically treated with prasugrel, where the prevalence
and predictors of suboptimal platelet inhibition on DAPT were
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addressed. We identified HRPR with prasugrel in about 10% of
patients and especially among patients with diabetes.
Recent advances in antiplatelet pharmacological therapies have
allowed the optimization of antithrombotic strategies, thus
reducing the rate of stent thrombosis and recurrent ischemic
events and providing significant benefits in the outcomes,
especially in the setting of ACS [20–22].
However, increasing complexity of current ACS patients is
rendering more and more challenging the balance between
bleeding and thrombosis in the choice of DAPT strategies [23–
25]. In fact, more advanced age and the higher rate of
comorbidities, such as diabetes or renal failure, have dramatically
raised the risk of bleeding complications, with negative con-
sequences on the survival [26]. Nevertheless, these subsets of
patients also display an enhanced pro-thrombotic status, with a
baseline elevated platelet reactivity that has been previously
associated with a suboptimal effectiveness of antiplatelet agents
and recurrent ischemic events [27].
Previous studies, in fact, have documented the occurrence of
HRPR in patients treated with DAPT, being associated with an
increased rate of recurrent acute ischemic events and periproce-
dural thrombotic complications in patients treated with coronary
stenting. In the recent collaborative analysis from different studies
on the role of platelet reactivity for risk stratification after
percutaneous coronary intervention, Aradi et al. [28] clearly
Table 1
Main clinical and demographic features in study population and according to platelet reactivity (HRPR) with prasugrel.
Clinical features Overall Prasugrel responders (n = 171) Prasugrel HRPR (n = 19) p-Value
Age (mean  SD) 62.8  9.2 63  9.3 61 8.4 0.37
BMI (mean  SD) 28.2  6.3 27.9  6.4 30.3  5 0.13
Male sex (%) 82.6 82.5 84.2 0.99
Hypertension (%) 72.6 72.5 73.7 0.99
Active smokers (%) 33.2 31.6 47.4 0.32
Diabetes mellitus (%) 30.5 27.5 57.9 0.015
Hypercholesterolemia (%) 55.8 55.6 57.9 0.99
Previous MI (%) 24.2 25.1 15.8 0.57
Previous PCI (%) 40 39.8 42.1 0.99
Previous CABG (%) 10.1 9.9 11.2 0.70
Renal failure (%) 7.9 8.8 0 0.37
ACS presentation (%) 61.4 61.8 57.9 0.95
ACE inhibitors (%) 54.5 57.1 31.6 0.05
ARBs (%) 21.7 20.6 31.6 0.26
Statins (%) 86.8 87.1 84.2 0.72
Beta blockers (%) 89.9 91.2 78.9 0.11
Nitrates (%) 42.9 42.9 41.1 0.99
Ca-antagonists (%) 28.6 26.5 47.4 0.07
Diuretics (%) 29.6 30.6 21.1 0.60
Ejection fraction (%  SD) 53.4  8.2 53.3  8.1 54.5  8.8 0.53
Left main/trivessel CAD 43.2 40.4 68.4 0.03
Main chemistry parameters
Glycemia (mean  SD) 117.7  36.9 116.3  36.5 131.2  38.8 0.11
HbA1c (mean  SD) 6.3 1 6.2 1 7 1.2 0.003
Creatinine (mean  SD) 0.91 0.3 0.91 0.3 0.88  0.2 0.59
Cholesterol HDL (mean  SD) 40  10.3 40.3 10.4 37.5  8.5 0.29
Cholesterol LDL (mean  SD) 74.6  0.3 72.4  22.9 94.6  48.2 0.001
C-reactive protein (mg/dl, mean  SD) 0.04 [0.13–0.42] 0.11 [0.04–0.37] 0.32 [0.05–0.72] 0.23
Platelets (105ml–1; mean  SD) 246.1 62 244.7 62.7 258.6  57.4 0.36
Hemoglobin (mean  SD) 13.7  1.9 13.7  1.9 14.1 1.2 0.30
WBC (103ml–1; mean  SD) 7.8  1.9 7.8  1.9 8.6  1.9 0.05
COL test (AUC; mean  SD) 417.3 160 395 144.7 608.2 160.8 <0.001
ASPI test (AUC; mean  SD) 377.3 187.7 353.5 171 590.4  200.2 <0.001
TRAP test (AUC; mean  SD) 1143.3  299 1112.6  288.7 1490.9  246.9 <0.001
ADP test (AUC; mean  SD) 282.2 152.5 243.9  83.6 626.7  193.5 <0.001
CAD, coronary artery disease; BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; STEMI,
ST-elevation myocardial infarction; ACS, acute coronary syndrome; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; LDL, low-density
lipoprotein; HDL, high-density lipoprotein; WBC, white blood cells.
Fig. 1. Bar graph showing the prevalence of residual high-on treatment platelet
reactivity in different subgroups of patients. DM, diabetes mellitus; CKD, chronic
kidney disease.
Table 2
Results of the multivariate model for the identification of the predictors of high-
platelet reactivity.
Variable OR 95% CI p-Value
HbA1c 2.1 1.32–3.33 0.002
LDL cholesterol 1.03 1.01–1.05 0.003
Diabetes mellitus 0.47 0.09–2.48 0.37
ACE-inhibitors 0.36 0.11–1.17 0.09
White blood cell count 1.18 0.89–1.56 0.26
Severe coronary artery disease 2.8 0.85–9.3 0.09
ACE, angiotensin-converting enzyme; LDL, low-density lipoprotein.
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showed in a cohort of over 20,000 patients undergoing PCI that
HRPR had significantly higher risk for stent thrombosis [risk ratio
(RR) and 95% CI: 2.73 (2.03–3.69), p < 0.00001], translating into
increased mortality.
However, the majority of clinical data in these patients were
obtained with clopidogrel, a pro-drug displaying a large inter-
individual variability of effect, due to the several genetic and
metabolic interactions with the processes leading to its activation
[29].
The introduction of ADP-antagonists, such as prasugrel and
ticagrelor, not requiring the same complex transformation as
clopidogrel, has certainly provided a faster and more predictable
platelet inhibition, thus translating into significant benefits in the
prevention of recurrent ischemic events [30]. However, still
suboptimal results have been achieved in higher thrombotic risk
subsets of patients, such as diabetics, where we have recently
reported a double rate of HRPR as compared to non-diabetic
patients also with the more potent ticagrelor [31].
Among the ADP-antagonists, instead, prasugrel has demon-
strated in the TRITON-TIMI 38 [32] a significant reduction in the
rate of major adverse events in ACS patients undergoing invasive
management, with even more positive results being achieved in
diabetics rather than for subjects without diabetes (net clinical
benefit with prasugrel 14.6% versus 19.2%; HR, 0.74; p < 0.001 in
diabetics, 11.5% versus 12.3%; HR, 0.92; p = 0.16 in non-diabetics, p
interaction = 0.05). An analogous conclusion, then, has been
reached by Rossington et al. [33] in a meta-analysis of 4 random-
ized trials on diabetic patients with ACS, where prasugrel could
reduce the rate of recurrent myocardial infarction, without
increasing the risk of major bleedings, especially among patients
managed with PCI.
Contrasting with the clinical data of TRITON-TIMI 38, instead,
Laine and colleagues [34] reported in 100 diabetic post-ACS
patients that ticagrelor achieved a significantly lower platelet
reactivity as compared to prasugrel loading dose. In addition,
similar results have been achieved by Alexopulos et al. in a cohort
of 777 patients [35], thus raising potential concerns on the problem
of suboptimal platelet inhibition also among prasugrel-treated
patients, and especially in settings at higher thrombotic risk.
However, the magnitude of the problem of HRPR on prasugrel
treatment is still largely undefined, with its rate varying among
studies according to the methods and definitions applied [13,36].
The present study reports the data of 190 patients on a chronic
maintenance therapy with prasugrel. We documented a rate of
HRPR with prasugrel of 10% of the patients by the use of MEA.
In the SWAP-3 trial [37], among the 77 patients analyzed on
prasugrel maintenance therapy, HRPR for prasugrel was 6.3% by
light transmission aggregometry (LTA), a test that still represents
the gold standard for assessing platelet function, with comparable
levels of platelet inhibition being achieved by ticagrelor. Similarly,
in the Optimizing anti-Platelet Therapy In diabetes MellitUS
(OPTIMUS)-3 trial, that compared platelet reactivity with high-
dose clopidogrel or prasugrel in a population of 35 diabetic
patients, at 7 days, the poor responder rate ranged from 2.9% to
21.2% for prasugrel [38].
In a similar cohort of post-ACS patients, Siller-Matula et al. [39]
documented HRPR with MEA aggregometry in 3% of the
107 subjects on prasugrel. However, their cohort included patients
with younger age and lower rate of diabetes, hypertension, and
other comorbidities as compared to our study, thus providing
potential explanation for the difference in the prevalence of
prasugrel poor-effectiveness. In fact, in a study by Cuisset et al.,
HRPR was much higher, occurring in about 8% of diabetic patients
treated with prasugrel [40], thus not much dissimilar to the
present results.
Moreover, in our study, we confirmed a higher rate of HRPR in
diabetic patients, with a significant interaction between diabetic
status and high platelet reactivity. However, at multivariate
analysis only poor glycemic control, but not diabetes per se,
emerged as an independent predictor of suboptimal platelet
inhibition on prasugrel. Thus, it might be hypothesized that
diabetic patients maintaining a good metabolic profile, could
achieve a satisfactory platelet inhibition on prasugrel, therefore
accounting for the positive results of this ADP-antagonist in the
TRITON-TIMI 38 trial.
Indeed, Alexopulos et al. [41] have previously documented in
233 patients that the independent predictors of HRPR on prasugrel
were the levels of baseline platelet reactivity, ACS at presentation,
and active smoking. In our cohort of patients, indication to DAPT
was an acute cardiovascular event in almost the overall cohort of
patients, and moreover, diabetic status and impaired glycemic
control can certainly have conditioned an elevation of baseline pre-
treatment platelet reactivity.
In fact, hyperglycemia can have an impact on platelet function
directly and by modulating the release of pro-oxidant and
inflammatory substances, inducing P-selectin expression and
amplification of platelet adhesion [42]. However, the strict
association between glucose control parameters and platelet
reactivity has been well established only in patients treated with
clopidogrel, where Singla et al. [43] have documented higher
platelet aggregation on DAPT in patients with HbA1c levels above
7%. On the contrary, no data on the topic have been so far reported
in prasugrel-treated patients, where the present study firstly
documents that the effectiveness of this antiplatelet drug can also
Fig. 2. Linear regression analysis displaying the relationship between area under the
curve (AUC) at ADP multiplate test in prasugrel-treated patients and glycosylated
hemoglobin (A, upper graph) and low-density lipoprotein cholesterol (LDL; B, lower
graph).
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be conditioned by glucose homeostasis. In effect, however, a
similar conclusion had been suggested from the TRITON-TIMI
38 study, reporting larger benefits from prasugrel among diabetic
patients treated with insulin (7.9% reduction in major adverse
events vs. 4.8% in the overall diabetic cohort) [44].
Therefore, more aggressive antiplatelet strategies, together
with a more rigorous control of other risk factors, such as glycemic
status, can certainly provide the largest advantages in patients
with acute cardiovascular events, and especially in higher risk
settings such as in diabetics.
Nevertheless, whether tailoring antiplatelet treatment according
to platelet reactivity will provide any significant improvement in the
outcomes is still a matter of debate [45,46], and future randomized
trials will certainly provide more conclusive indications for the
management of these patients at higher thrombotic risk.
Limitations
A first limitation can be considered the relatively small sample
size. However, as we aimed to describe the prevalence of a
phenomenon in a real-world setting, where few data have been
reported so far, we preferred not to perform a sample size
estimation. However, our study represents one of the largest
cohorts of patients where platelet function was assessed and
moreover our conclusions were consistent with previous reports
on the topic [38]. Indeed, the reduced number of patients in certain
higher-risk subsets of patients, such as subjects with renal failure,
and the greater statistical power for continuous variables, could
potentially have affected the conclusions of our multivariable
model, however the independent predictors of HRPR in our
findings are in line with the data achieved in similar studies with
other antiplatelet agents [43,47].
Another limitation can be considered the timing of platelet
aggregation. The choice of evaluating patients on chronic
antiplatelet therapy, after at least one month, was made on
purpose, as Gurbel et al. [48] previously reported that the
prevalence of HRPR on antiplatelet therapy progressively de-
creased within the first 30 days of treatment.
In addition, our results in patients with HRPR were not
confirmed by using LTA, that still represents the gold standard
for platelet aggregation. However, a good correlation between
ADP-mediated impedance platelet aggregometry and ADP-LTA has
already been reported [49].
In our study, elderly patients and subjects with low body
weight, representing potential indications to the adjustment of
prasugrel dose, were excluded, and therefore data on these
categories cannot be provided from the present study, as we
wanted to enroll a population receiving a standardized prasugrel
dose of 10 mg.
Finally, we did not perform a systematic follow-up of our
patients and therefore, we cannot definitely evaluate the impact of
prasugrel non-responsiveness on clinical outcomes.
Conclusions
In post-ACS patients treated with PCI and receiving DAPT with
prasugrel, HRPR is not infrequent, occurring in about 10% of
patients. Impaired metabolic status, and especially elevated
glycosylated hemoglobin, emerged as the only independent
predictor of suboptimal effectiveness of prasugrel.
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